[email protected] Dr. Axel Unterbeck joined Oxford Bioscience Partners as an Entrepreneur-in-Residence in 2005. Prior to joining Oxford, Dr. Unterbeck was President, Chief Scientific Officer, and Co-Founder at Memory Pharmaceuticals, Corp which achieved its initial public offering in April of 2004, NASDAQ: MEMY. Dr. Unterbeck has over 19 years of R&D; experience within the pharmaceutical and biotechnology industry. He held various positions within CNS R&D; at Bayer AG in Germany and the US, including Head of CNS/Dementia Research. Prior to joining Bayer AG, Dr Unterbeck was a member of the scientific team at the Institute for Genetics in Cologne which achieved the first full-length cloning of the human amyloid precursor protein (APP) gene implicated in Alzheimer’s disease. He received his Ph.D. in Molecular Biology/ Genetics at the University of Cologne and his MS/BS degree in Biology at the University of Bonn.